ABCL
Price
$11.80
Change
-$0.88 (-6.94%)
Updated
Oct 16 closing price
Capitalization
4.51B
23 days until earnings call
Intraday BUY SELL Signals
MRVI
Price
$6.79
Change
-$0.28 (-3.96%)
Updated
Oct 16 closing price
Capitalization
1.14B
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs MRVI

ABCL vs MRVI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. MRVI commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and MRVI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABCL with price predictions
Oct 16, 2026

ABCL's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for ABCL moved out of overbought territory on October 01, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 27 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

ABCL moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ABCL broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 204 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 134 of 165 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.035) is normal, around the industry mean (26.782). P/E Ratio (11.976) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (437.542).

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MRVI with price predictions
Oct 16, 2026

Aroon Indicator for MRVI shows an upward move is likely

MRVI's Aroon Indicator triggered a bullish signal on October 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator showed a similar pattern. In 157 of the 172 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for MRVI crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 84%.

Following a +8.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 208 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

MRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for MRVI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 29 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRVI as a result. In 77 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for MRVI turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

MRVI moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.556) is normal, around the industry mean (26.782). P/E Ratio (28.333) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (437.542).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABCL vs MRVI: Fundamental Ratings
ABCL
MRVI
OUTLOOK RATING
1..100
7226
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
3436
P/E GROWTH RATING
1..100
715
SEASONALITY SCORE
1..100
3n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABCL's Valuation (69) in the null industry is in the same range as MRVI (79). This means that ABCL’s stock grew similarly to MRVI’s over the last 12 months.

ABCL's Profit vs Risk Rating (100) in the null industry is in the same range as MRVI (100). This means that ABCL’s stock grew similarly to MRVI’s over the last 12 months.

ABCL's SMR Rating (94) in the null industry is in the same range as MRVI (97). This means that ABCL’s stock grew similarly to MRVI’s over the last 12 months.

ABCL's Price Growth Rating (34) in the null industry is in the same range as MRVI (36). This means that ABCL’s stock grew similarly to MRVI’s over the last 12 months.

MRVI's P/E Growth Rating (5) in the null industry is significantly better than the same rating for ABCL (71). This means that MRVI’s stock grew significantly faster than ABCL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABCLMRVI
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (ABCL: $11.80 vs. MRVI: $6.79)
Brand notoriety: ABCL and MRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 74% vs. MRVI: 63%
Market capitalization -- ABCL: $4.51B vs. MRVI: $1.14B
ABCL [@Biotechnology] is valued at $4.51B. MRVI’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green while MRVI’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • MRVI’s FA Score: 1 green, 4 red.
According to our system of comparison, MRVI is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while MRVI’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 6 bearish.
  • MRVI’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MRVI is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -5.94% price change this week, while MRVI (@Biotechnology) price change was -8.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 09, 2026.

MRVI is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABCL
Daily Signal:
Gain/Loss:
MRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USVN45.920.05
+0.11%
US Treasury 7 Year Note ETF (USVN)
CGVV31.40-0.18
-0.57%
Capital Group U.S. Large Value ETF
BLW11.52-0.13
-1.12%
Blackrock Limited
NSI36.50-0.62
-1.67%
National Security Emerging Markets Index ETF (NSI)
BOTZ33.02-0.72
-2.13%
Global X Robotics & Artificial Intelligence ETF (BOTZ)

MRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with MRNA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRVI
1D Price
Change %
MRVI100%
-3.96%
MRNA - MRVI
45%
Loosely correlated
-7.82%
BNTX - MRVI
41%
Loosely correlated
-2.76%
TWST - MRVI
39%
Loosely correlated
-8.13%
RXRX - MRVI
39%
Loosely correlated
-16.71%
NVAX - MRVI
39%
Loosely correlated
-12.17%
More